Summary: In a double-blind randomised trial in diabetic foot ulcers, wound-blotting-guided biofilm management added to standard care significantly improved the DMIST wound score at week 3 and increased biofilm removal in the first two weeks, supporting biofilm as a treatable barrier to healing.
PICO Summary
| Element | Detail |
|---|---|
| Population | 162 adults with diabetes and a foot ulcer present at least two weeks, below the knee; outpatient clinic, Pontianak, Indonesia. |
| Intervention | Standard care plus wound-blotting-guided biofilm management: targeted cleansing per blotting result and antimicrobial dressing, weekly for three weeks. |
| Comparison | Standard care with appropriate dressings. |
| Outcome | Significant between-group difference in total DMIST wound score at week 3 (p<0.01) and in biofilm percentage reduction at week 1 (p=0.01) and week 2 (p=0.03), favouring biofilm-guided care. |
Biofilm-guided wound care in diabetic foot ulcers
Double-blind RCT · diabetic foot ulcers · 3 weeks
Adding wound-blotting-guided biofilm management to standard care significantly improved the composite DMIST wound score by week 3 and accelerated biofilm removal in the first two weeks. Follow-up was short at 3 weeks and the bundle cannot isolate the detection step.
Expert Commentary
Biofilm is a real and under-treated obstacle in chronic wounds, so a trial testing whether point-of-care detection can guide more effective removal is welcome, and this double-blind randomised study with 162 patients is a reasonable size for the field. I lean positive: a significant improvement in the composite DMIST wound score by week three, alongside greater biofilm reduction in the first two weeks, fits the biological logic that clearing the biofilm barrier lets healing proceed. Two honest caveats. The intervention bundles several things, targeted cleansing plus antimicrobial dressing, so it cannot isolate the contribution of the detection step itself, and the follow-up is short at three weeks, with DMIST being a wound-assessment score rather than confirmed complete closure. The authors themselves call for a longer, twelve-week evaluation. I will also note that the earlier write-up’s mention of skin irritation as the main adverse effect does not reflect this study and has been removed. Can I use this with my patients? Cautiously yes, in the sense that it reinforces treating biofilm actively in stalled diabetic foot ulcers through sharp debridement and antimicrobial dressings, within full offloading and vascular care, even where wound-blotting technology is not available. Longer outcome data would strengthen the case.
References
Astrada A, Nakagami G, Kashiwabara K, Sanada H. Biofilm detection-based wound management in diabetic foot ulcers: a randomised controlled trial. J Wound Care. 2025;34(7):514–524. doi:10.12968/jowc.2024.0051